1-[(N,N-dimethylamino)benzene-4-sulfonyl]-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole | 259183-24-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[(N,N-dimethylamino)benzene-4-sulfonyl]-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
• 英文别名: 1-[(N,N-dimethylamino)benzene-4-sulfonyl]-6-methoxy-2-[[(3,5-dimethyl-4-methoxy-pyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole；1-[(N,N-dimethylamino)benzene-4-sulfonyl]-6-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole；4-[6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-1-yl]sulfonyl-N,N-dimethylaniline
• CAS: 259183-24-9
• 化学式: C₂₅H₂₈N₄O₅S₂
• 分子量: 528.653
• InChiKey: CHTPTCMXOFRPJG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  131
• 氢给体数：
  0
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  4-(二甲基氨基)苯-1-磺酰氯 、 奥美拉唑 生成 1-[(N,N-dimethylamino)benzene-4-sulfonyl]-5-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole 、 1-[(N,N-dimethylamino)benzene-4-sulfonyl]-6-methoxy-2-[(3,5-dimethyl-4-methoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
  参考文献：
  名称：

  1-Arylsulfonyl-2-(Pyridylmethylsulfinyl) Benzimidazoles as New Proton Pump Inhibitor Prodrugs

  摘要：

  我们合成了新的芳基磺酰基质子泵抑制剂（PPI）原药。这些原药能延长 PPI 有效血浆浓度的停留时间，从而提高胃酸抑制效果。

  DOI：

  10.3390/molecules14125247

文献信息

• PRODRUGS OF PROTON PUMP INHIBITORS
  申请人：Winston Pharmateuticals LLC

  公开号：EP1105387B1

  公开（公告）日：2003-01-29
• US6559167B1
  申请人：——

  公开号：US6559167B1

  公开（公告）日：2003-05-06
• [EN] PRODRUGS OF PROTON PUMP INHIBITORS<br/>[FR] PROMEDICAMENTS D'INHIBITEURS DE LA POMPE A PROTONS
  申请人：PARTNERSHIP OF MICHAEL E GARST

  公开号：WO2000009498A1

  公开（公告）日：2000-02-24

  Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.